Research Area: Checkpoint & combination therapy
Development Stage: Discovery
Goal: Identify subtle differences and mechanism in therapies that engage T cells and the tumor microenvironment
to follow our data >[/ce_button]
PSI identified T cell potency upregulation triggered by novel bispecifics and revealed unique T cell cytokine mechanisms in response to tumor target. PSI was computed for CD4+ and CD8+ T cells; the profiles of both B2-OKT3 and hNKG2D-OKT3 showed significant polyfunctional upregulation relative to the Tz47-2C11 control sample, indicating their effectiveness in triggering a potent T cell response.
Both bispecific profiles are dominated by effector cytokines. hNKG2G-OKT3 stimulation is more potent in terms of polyfunctional strength index (PSI) than B2-OKT3, and sources of upregulation are revealed through the differential cytokine profile (i.e. chemoattractive and effector cytokines). CD4+ and CD8+ cells show the same trend and almost identical cytokine secretion with the exception of IL-5.1
to learn more >[/ce_button]
PAT PCA visualization illustrates the differential T cell upregulation triggered by novel hNKG2D-OKT3 and B2-OKT3 bispecifics, by identifying highly functional cell subsets. CD4+ T cells from the hNKG2D-OKT3 group (orange) secreted polyfunctional effector proteins more frequently than those cultured in the presence tumor cells and the B2-OKT3 bispecific (blue).
This hNKG2D-OKT3 polyfunctionality includes diverse combinations of secretions, whereas B2-OKT3 overall elicited fewer polyfunctional and more monofunctional secretions. The increased polyfunctional response and T cell potency driven by hNKG2D-OKT3 indicates its potential superiority over B2-OKT3.1